Amphastar Pharmaceuticals (AMPH) Payables (2013 - 2026)

Amphastar Pharmaceuticals has reported Payables for 14 years, with the latest figure at $251.4 million in Q2 2026.

• On a quarterly basis, Payables rose 50.93% year-over-year to $251.4 million in Q2 2026; TTM through Jun 2026 was $251.4 million, a 50.93% increase from a year earlier, with the FY2025 full-year figure at $148.3 million, down 5.55% from the prior year.
• Payables was $251.4 million for Q2 2026 at Amphastar Pharmaceuticals, up from $152.7 million in the prior quarter.
• The five-year high for Payables was $251.4 million in Q2 2026, with the low at $84.2 million in Q4 2022.
• Average Payables over 5 years is $146.7 million, with a median of $150.5 million recorded in 2025.
• The sharpest annual moves came in 2023 and 2024: Payables jumped 132.49% in 2023, then tumbled 39.68% in 2024.
• Over 5 years, Payables stood at $84.2 million in 2022, then gained by 10.83% to $93.4 million in 2023, then jumped by 68.22% to $157.1 million in 2024, then retreated by 5.55% to $148.3 million in 2025, then jumped by 69.45% to $251.4 million in 2026.
• The last three Payables figures came in at $251.4 million (Q2 2026), $152.7 million (Q1 2026), and $148.3 million (Q4 2025), per Business Quant data.